One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Electromed logo
Electromed ELMD
$ 27.48 0.75%
report update icon

Quarterly report 2026-Q4
added 08-25-2026

Electromed Financial Ratios 2026-2010 | ELMD

Brief overview of Electromed's financial ratios

This overview follows the five latest available observations from 2021 through 2025.

The latest available valuation ratios are P/E 23.17x (median 26.68x), EV/EBITDA 15.89x (median 18.38x), P/S 2.73x (median 2.51x). On average, this basket is 13.2% below its own five-year medians. The market values the business at a discount to recent history.

The 1/P/E calculation produces a 4.3% earnings yield. It does not capture future growth or capital structure.

The latest available business-quality ratios are ROE 17.4%, ROA 14%, ROCE 22.4%. Overall capital returns are high. The business uses resources efficiently and provides strong fundamental support for its valuation.

Price, earnings and growth produce a PEG of 1.2x, a neutral level if forecasts are realistic.

The cash conversion cycle shortened from 238.5 days to 180.2 days, or 58.2 days. Working capital returns faster.

Valuation takeaway

Electromed combines solid capital returns with a discount to its own history. The main question is whether earnings and growth are sustainable.

Annual Financial Ratios Electromed

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

P/E

28.8 23.2 26.7 26.2 33.9 43.5 35.5 22.6 22.7 22.6 16.4 13.4 -8.8 -7.3 86.9 25.2 -

P/S

4.4 2.7 2.5 1.7 1.9 2.9 4.6 1.4 1.5 1.9 1.6 0.8 0.7 0.6 0.8 1.4 -

EPS

1.4 0.9 0.6 0.4 0.3 0.3 0.5 0.2 0.2 0.3 0.3 0.1 -0.2 -0.2 0.0 0.1 -

EV (Enterprise Value)

317 M 170 M 129 M 83.8 M 77.2 M 95.6 M 140 M 40.3 M 40.5 M 48.7 M 35.3 M 14.5 M 12.8 M 12.8 M 20.4 M 28.6 M -611 K

EBITDA per Share

1.78 1.27 0.86 0.54 0.41 0.42 0.697 0.451 0.463 0.529 0.473 0.252 -0.00555 -0.153 0.14 0.297 -

EV/EBITDA

21.5 15.9 17.5 18.4 22.2 26.4 23.4 9.8 9.7 10.6 8.4 6.0 -245.8 -8.5 14.2 10.6 -

PEG

0.82 1.2 1.29 3.15 -63.34 18.7 0.33 5.19 -1.53 -31.38 0.16 0.07 -36.07 0.01 -1.04 -3.78 -

P/B

6.0 4.0 3.1 2.2 2.3 3.2 4.9 1.7 2.0 2.6 2.2 1.0 0.9 0.7 1.1 1.8 -

P/CF

33.6 15.3 15.2 63.1 -114.0 33.4 45.9 37.0 23.1 99.8 22.8 6.8 10.0 11.7 -8.0 -10.5 -

ROE %

20.94 17.44 11.56 8.41 6.75 7.29 13.76 7.65 8.69 11.69 13.53 7.85 -10.13 -9.54 1.24 7.18 -

ROA %

17.05 14.01 9.86 6.91 5.57 6.37 12.52 6.71 7.14 9.67 10.75 6.28 -8.16 -7.57 0.89 5.06 -

ROCE %

25.72 22.36 14.77 10.64 8.70 9.69 16.92 10.95 13.74 17.70 17.75 8.66 -5.30 -11.90 3.62 11.36 -

Current Ratio

5.4 5.1 6.8 5.6 5.8 7.9 9.4 6.8 4.7 6.4 5.1 5.5 5.8 5.7 3.9 3.8 -

DSO

134.7 136.9 158.3 171.5 166.8 153.0 158.6 160.4 147.1 140.4 123.9 122.6 152.9 230.8 209.2 184.3 -

DIO

80.5 91.2 111.5 116.9 94.5 112.3 154.9 128.4 147.5 176.5 177.0 130.2 168.1 108.2 162.3 129.6 -

DPO

61.2 47.8 33.5 41.6 34.8 26.8 27.9 28.7 50.7 45.7 42.0 33.8 28.6 50.5 50.9 51.2 -

Operating Cycle

215.2 228.1 269.8 288.5 261.4 265.2 313.4 288.8 294.6 316.9 300.9 252.8 321.0 339.0 371.5 313.9 -

Cash Conversion Cycle

154.0 180.2 236.3 246.9 226.6 238.5 285.5 260.1 243.9 271.2 258.8 219.0 292.4 288.5 320.7 262.6 -

All numbers in USD currency

Quarterly Financial Ratios Electromed

2026-Q4 2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

- 0.37 0.33 0.26 0.33 0.26 - 0.22 0.23 0.17 - 0.17 0.2 0.02 - 0.13 0.12 0.01 0.13 0.08 0.1 0.05 0.15 0.03 0.14 0.06 0.14 0.06 0.14 0.12 0.14 0.12 0.05 0.02 0.05 0.02 0.05 0.01 0.04 0.01 0.05 0.02 0.05 0.02 0.13 0.04 0.13 0.04 0.05 0.05 0.05 -0.12 -0.03 -0.04 -0.07 -0.05 -0.05 0.05 -0.05 0.01 - 0.03 0.03 0.06

EBITDA per Share

- 0.54 0.49 0.35 - 0.35 - - - 0.25 - - - 0.04 - - 0.15 0.02 0.19 0.1 0.13 0.08 0.22 0.03 0.18 0.09 0.21 0.09 0.19 0.18 0.22 0.18 0.08 0.04 0.12 0.04 0.09 0.03 0.13 0.04 0.09 0.05 0.13 0.05 0.15 0.09 0.19 0.09 0.06 0.07 0.09 0.07 -0.04 -0.06 -0.01 -0.06 -0.07 - -0.04 - 0.01 0.07 0.04 0.07

ROE %

16.96 23.03 21.70 19.93 19.67 17.14 12.37 15.88 15.73 11.62 8.06 11.02 10.27 6.36 5.95 9.05 7.99 7.73 8.82 9.67 9.10 10.26 12.65 12.43 12.84 13.34 13.79 14.23 16.26 13.69 11.11 8.53 5.44 5.87 4.69 4.85 4.81 5.36 6.10 7.06 7.61 11.94 13.18 18.14 19.42 15.62 16.11 11.77 12.29 7.39 2.05 -2.99 -8.37 -9.39 -7.40 -8.41 -6.47 -3.51 -1.40 1.49 3.64 1.64 0.17 1.67

ROA %

14.06 19.09 18.02 16.60 16.38 14.37 10.38 13.44 13.40 9.98 6.97 9.48 8.79 5.42 5.07 7.63 6.77 6.61 7.56 8.45 7.98 9.14 11.48 11.66 12.09 12.49 12.90 13.32 15.16 12.81 10.27 7.62 4.73 5.09 4.06 4.20 4.16 4.53 5.15 5.80 6.20 9.66 10.63 14.60 15.63 12.56 12.91 9.46 9.89 5.98 1.77 -2.27 -6.57 -7.35 -5.77 -6.37 -4.80 -2.53 -1.03 1.06 2.57 1.16 0.12 1.18

ROCE %

21.59 29.56 27.87 24.77 24.63 21.34 15.37 19.70 20.44 14.98 10.31 13.59 12.87 7.39 7.02 10.88 10.13 9.74 11.24 12.36 10.56 12.16 12.58 12.50 13.91 14.60 17.29 17.90 20.75 18.08 14.19 11.51 7.37 8.25 7.90 8.94 8.92 9.43 10.67 11.26 12.19 16.05 18.41 22.92 25.36 20.57 19.51 14.05 12.98 7.38 0.11 -5.62 -12.90 -14.65 -11.06 -12.79 -9.28 -4.56 -0.91 3.72 7.44 3.01 0.68 3.08

Current Ratio

5.1 5.8 5.8 6.0 5.8 6.0 5.1 6.2 6.0 6.6 6.8 7.7 7.1 7.5 5.6 6.7 6.8 6.7 5.8 7.8 8.1 7.8 7.9 7.9 10.3 9.7 11.1 11.1 10.4 9.1 8.0 8.0 - - 5.8 7.3 6.3 6.1 5.8 5.8 6.0 6.5 4.9 4.9 5.3 5.3 5.0 5.0 5.3 4.8 5.1 5.1 4.4 4.6 4.8 4.8 4.3 3.8 3.6 3.6 3.7 3.4 3.4 3.4

DSO

- 114.6 112.7 134.0 123.2 133.5 - 134.4 126.7 142.2 - 154.2 154.8 176.2 - 166.0 165.4 179.8 82.9 174.2 166.8 161.5 76.8 168.4 139.4 151.4 124.3 146.3 135.8 140.0 136.2 135.7 133.7 146.5 134.5 134.8 126.6 141.8 130.0 130.4 116.9 128.8 109.0 119.4 97.3 118.4 95.0 119.9 121.4 122.9 121.3 129.4 195.9 227.0 234.9 250.1 238.3 240.7 256.8 244.0 201.0 169.6 182.7 -

DIO

- 78.4 80.9 89.4 80.9 87.4 - 79.9 81.9 102.6 - 116.9 134.1 140.5 - 104.9 107.0 134.3 44.7 73.8 73.5 82.1 41.3 103.2 131.2 151.2 142.8 141.0 131.6 124.9 127.8 124.7 130.5 140.2 116.4 128.5 141.7 141.8 167.1 162.0 163.4 190.6 156.6 182.6 152.2 168.9 138.7 172.1 138.2 138.5 138.0 139.2 172.6 120.8 128.7 140.8 142.9 177.1 162.7 180.6 159.0 140.1 129.2 -

DPO

- 57.0 61.1 67.5 61.1 71.8 - 44.7 41.4 40.1 - 24.0 30.4 39.2 - 31.4 30.7 49.5 20.6 46.8 49.2 38.6 13.4 30.8 34.5 32.5 25.7 28.7 40.4 38.0 28.6 30.2 36.6 43.7 37.9 39.9 40.4 38.0 43.3 35.7 28.1 38.0 37.2 45.3 38.2 42.4 36.0 40.7 39.0 35.9 23.5 52.0 105.1 68.5 60.1 60.0 44.4 49.1 51.0 51.8 48.2 52.0 51.1 -

Operating Cycle

- - - - 204.1 220.9 - 214.3 208.6 244.8 - 271.1 288.9 316.6 - 270.9 272.4 314.2 127.6 248.0 240.3 243.5 118.1 271.6 270.6 302.6 267.2 287.3 267.4 264.9 264.1 260.4 264.2 286.7 250.9 263.3 268.4 283.6 297.1 292.3 280.3 319.4 265.6 302.0 249.6 287.3 233.7 292.0 259.6 261.4 259.2 268.6 368.4 347.7 363.7 390.9 381.2 417.8 419.4 424.5 360.0 309.6 312.0 -

Cash Conversion Cycle

- - - - 143.0 149.2 - 169.6 167.3 204.7 - 247.2 258.4 277.4 - 239.4 241.7 264.6 107.0 201.3 191.1 204.9 104.7 240.8 236.2 270.1 241.4 258.6 227.0 226.9 235.5 230.2 227.6 243.0 212.9 223.4 227.9 245.6 253.8 256.6 252.1 281.4 228.4 256.7 211.3 244.9 197.6 251.3 220.6 225.4 235.8 216.6 263.4 279.3 303.6 330.9 336.8 368.6 368.4 372.7 311.8 257.6 260.9 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Electromed, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Orthofix Medical Orthofix Medical
OFIX
$ 9.25 0.05 % $ 366 M curacaoCuracao
TransMedics Group TransMedics Group
TMDX
$ 75.52 1.23 % $ 2.57 B usaUSA
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
Abbott Laboratories Abbott Laboratories
ABT
$ 102.97 0.29 % $ 179 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Venus Concept Venus Concept
VERO
- - $ 726 K usaUSA
Zynex Zynex
ZYXI
- - $ 21.1 M usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 5.05 0.67 % $ 3.4 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Align Technology Align Technology
ALGN
$ 144.44 0.63 % $ 10.5 B usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 2.57 2.32 % $ 106 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.18 0.19 % $ 22.1 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 10.44 0.66 % $ 1.57 B usaUSA
Butterfly Network Butterfly Network
BFLY
$ 7.6 3.64 % $ 1.88 B usaUSA
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
Bio-Rad Laboratories Bio-Rad Laboratories
BIO
$ 362.43 0.13 % $ 9.88 B usaUSA
AxoGen AxoGen
AXGN
$ 35.14 0.26 % $ 1.62 B usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Bruker Corporation Bruker Corporation
BRKR
$ 55.6 0.89 % $ 8.44 B usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 9.24 0.38 % $ 262 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 3.09 0.26 % $ 192 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 44.93 0.02 % $ 1.39 B usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
Establishment Labs Holdings Establishment Labs Holdings
ESTA
$ 57.88 0.66 % $ 1.71 B costa-ricaCosta-rica
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Viveve Medical Viveve Medical
VIVE
- -15.35 % $ 1.71 M usaUSA
ViewRay ViewRay
VRAY
- 1.54 % $ 468 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA
SeaSpine Holdings Corporation SeaSpine Holdings Corporation
SPNE
- 0.28 % $ 270 M usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA